acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They will pay it back in cash from the secondary offering that will occur sooner than you think.
The company lost almost $3,000,000 in the first nine months of 2012 and probably more than $4,000,000 for the full year.
You should have sold at .19. :(
p.s. Once it goes below .08 it will drop to .06 very fast.
Over 2,000,000 shares traded today and price is at .02. Someone wants in.
I still think there are new investors on board now.
Good luck to all the "BONZ" faithful.
Good days ahead.
The shorts/sellers are walking this down to perfection. Squeezing every penny out of gullible retail investors.
I chuckled when I saw that the "bridge financing" had been increased to $2,000,000 with a conversion price of .10.
That is how penny stock companies get retail investors to over pay for shares and prop up the share price.
It's highly unlikely that the debt will ever convert at .10 but will be paid from the dilutive secondary offering which the company is pursuing for $15,000,000 as previously stated at the One Med Forum.
The .10 is taunted by the "pumpers" by saying that investors were willing to invest $2,000,000 for the right to convert at .10 so why wouldn't you purchase shares for .10?
I expect the new secondary will involve shares in the .06 range.
I'd wait to buy below .04 after it is announced.
All imho.
Buy at .035 after the dilutive funding is announced.
1,000,000,000 shares is a lot of shares.
Today's Seeking Alpha - Market Watch
"Good news for shareholders is that Oppenheimer came out yesterday and stated that based on the closing price Friday that the shares presented an attractive entry point. The firm also stated that they had an $11/share price target on the shares and believes that the company's financing does not preclude it from selling itself but rather strengthens its position in negotiations with any potential acquirers or partners as they now have a cash reserve to hold them over."
If you're waiting for $4.00 then you might as well be waiting for $1.00.
Buying today. This is substantially oversold.
Shorts will start locking in profits. Should be back above $8.00 by Friday.
GLTA
I suspect this will start gaining some traction to the upside in anticipation of news confirming that some of your expectations are based in reality.
Another day closer to great news. :)
Good things come to those that wait.
Add a few shares under .02 before they're gone.
New investors from China may be arriving sooner than expected.
No dilution required. :)
Just saying.
p.s. Show us the money!!!
Another "RED" day for the longs.
Down 60% from its recent high and falling.
Dropping price and dropping volume. The traders are selling and moving on.
You may want to take some profits if you have any left.
All imho.
The following summary explains why it will be years and many millions of dollars invested before a determination is made that the MANF technology offers any benefits.
"Before MANF treatment can be considered for clinical applications there are several questions that need to be addressed. Prophylactic treatment capable of dampening the pathological responses to ischemia may be therapeutically important for only small number of patients who are highly prone to ischemic attacks. Before preclinical post-stroke experiments are conducted there are “proof of principle” questions that need to be addressed. Delivery to the intact brain via the ventricular system, vascular system or intranasal route needs further development. The increased permeability of blood brain barrier (BBB) after the onset of stroke, provides a window to target ischemic brain tissue for compounds that normally do not cross BBB. Other problems that need to be studied include the ability of post-stroke MANF delivery to promote recovery, timing of administration after stroke, and efficacy of coadministration of MANF with other treatments, like physical therapy or exercise, to promote recovery. Also, pre-clinical studies of MANF in other animal models of ischemic brain injury are needed. After these issues are addressed, safety, tolerance and efficacy of delivery should be evaluated in humans. Ultimately, a clinical study in a small number of stroke patients could be considered."
I chuckled when I saw that the "bridge financing" had been increased to $2,000,000 with a conversion price of .10.
That is how penny stock companies get retail investors to over pay for shares and prop up the share price.
It's highly unlikely that the debt will ever convert at .10 but will be paid from the dilutive secondary offering which the company is pursuing for $15,000,000 as previously stated at the One Med Forum.
The .10 is taunted by the "pumpers" by saying that investors were willing to invest $2,000,000 for the right to convert at .10 so why wouldn't you purchase shares for .10?
I expect the new secondary will involve shares in the .06 range.
I'd wait to buy below .04 after it is announced.
All imho.
Bottom should be in the .035 range when the major funding is announced.
The company's stated goal at the One Med Forum was to raise $15,000,000.
I'd wait to place a bet.
GLTY
The MANF technology is years and millions of dollars away from yielding a potential useful drug. The company recently increaed the number of authorized shares to a billion in anticipation of raising funds.
Conclusion from a recent study:
"Before MANF treatment can be considered for clinical applications there are several questions that need to be addressed. Prophylactic treatment capable of dampening the pathological responses to ischemia may be therapeutically important for only small number of patients who are highly prone to ischemic attacks. Before preclinical post-stroke experiments are conducted there are “proof of principle” questions that need to be addressed. Delivery to the intact brain via the ventricular system, vascular system or intranasal route needs further development. The increased permeability of blood brain barrier (BBB) after the onset of stroke, provides a window to target ischemic brain tissue for compounds that normally do not cross BBB. Other problems that need to be studied include the ability of post-stroke MANF delivery to promote recovery, timing of administration after stroke, and efficacy of coadministration of MANF with other treatments, like physical therapy or exercise, to promote recovery. Also, pre-clinical studies of MANF in other animal models of ischemic brain injury are needed. After these issues are addressed, safety, tolerance and efficacy of delivery should be evaluated in humans. Ultimately, a clinical study in a small number of stroke patients could be considered."
LOL!!! The share price is down 60% from its recent high. It seems to me the desperate ones are those that own it above the current price as it continues to fall towards two cents.
Wait until the major dilution is announced before placing a bet.
I'm thinking the next secondary offering will have shares sold for .06 or less.
15 years and up to $1.7 billion dollars. Now you know why the company needed to authorize 1,000,000,000 shares.
http://www.pdpipeline.org/2011/Eithics/navagating/regulatory.htm
The company is currently almost at this level:
Pre-Clinical research and animal testing
The drug development process starts with a sponsor, usually a pharmaceutical company, seeking to develop a new compound it hopes will find a useful and profitable place in the market. Before an investigational drug can be tested in humans, researchers must prove that the compound is safe for use in small-scale, human clinical studies by first analyzing its physical and chemical properties in the laboratory and assessing its safety and therapeutic efficacy in animals.
Animal testing reveals what, if any, affect the drug has on a disease or its symptoms and at what dosage levels; the rate of absorption, metabolism, and elimination; and the drug’s therapeutic effect. Generally, two or more species of animals are tested because a drug may affect one species differently from another. Testing ranges from a few weeks to several years. Some animal testing even continues after human tests have begun in order to evaluate whether long-term use of the drug may cause cancer or birth defects. Since animals have a much shorter lifespan than humans, valuable information can be gained about a drug’s effects over an animal’s life cycle.
If the results of laboratory and animal study are promising, the treatment sponsor can file an Investigational New Drug application asking the FDA to approve human clinical trials.
The following summary explains why it will be years and many millions of dollars invested before a determination is made that the MANF technology offers any benefits.
"Before MANF treatment can be considered for clinical applications there are several questions that need to be addressed. Prophylactic treatment capable of dampening the pathological responses to ischemia may be therapeutically important for only small number of patients who are highly prone to ischemic attacks. Before preclinical post-stroke experiments are conducted there are “proof of principle” questions that need to be addressed. Delivery to the intact brain via the ventricular system, vascular system or intranasal route needs further development. The increased permeability of blood brain barrier (BBB) after the onset of stroke, provides a window to target ischemic brain tissue for compounds that normally do not cross BBB. Other problems that need to be studied include the ability of post-stroke MANF delivery to promote recovery, timing of administration after stroke, and efficacy of coadministration of MANF with other treatments, like physical therapy or exercise, to promote recovery. Also, pre-clinical studies of MANF in other animal models of ischemic brain injury are needed. After these issues are addressed, safety, tolerance and efficacy of delivery should be evaluated in humans. Ultimately, a clinical study in a small number of stroke patients could be considered."
Is it possible there's a third well that we don't know about on the Tarantula site.
Possibly someone with expertise in regards to wells located on remote mining sites in Arizona could research this for the next six months and let the board know if it really exists. Daily updates would be appreciated.
p.s. Is it possible that a storage shed could have been placed over the well so as to hide it from "Google Earth" surveillance? Only honest and informed opinions please.
The bottom should be in the .035-.04 range in the short term.
I'll consider getting back in for the long run after the terms of the $15,000,000 funding are announced and the stock bottoms.
Until then I don't see any upside especially to just buy and hold the stock.
GLTY
p.s. I hope you make a lot of money in the long run because that means I will have also.
The increase in the "bridge financing" to $2,000,000 with a conversion price of .10 put a cap on the upside.
The $15,000,000 financing that the company is seeking will more than likely be in the .06-.07/share range. 225,000,000 shares?
The market typically discounts the share price 40% from the secondary pricing.
.035-.04 is at or near the bottom.
If you want to buy shares at .08 then I'm certain there's a short that will appreciate your doing so.
All imho.
p.s. 1,000,000,000 shares is a lot of shares.
How about a moment of silence for all those individuals that bought millions of shares above the current share price with virtually no hope of recovering their losses.
Sometimes the data is so good that you want to get a second opinion before releasing it. :)
It appears that the "sky rocket" is crashing to earth. :(
1,000,000,000 shares is a lot of shares.
Dropping volume as the traders have moved on and there are millions of shares of "overhang" now held at substantial losses.
"Patience is a virtue."
"The trend is your friend."
.19
.18
.17
.16
.15
.14
.13
.12
.11
.10
.09
.08
Dropping share price and dropping volume. :(
A study on a few rats doesn't qualify as pre-clinical trials.
Have to go.
Have a great day!!
p.s. Share price is headed back to .03.
At a minimum it would probably be eight to ten years and a billion dollar investment to get a drug based on MANF technology to the market.
Odds are 1 in 5,000 that it happens.
All imho.
How many years and how many millions of dollars will it take to accomplish this?
"Before MANF treatment can be considered for clinical applications there are several questions that need to be addressed. Prophylactic treatment capable of dampening the pathological responses to ischemia may be therapeutically important for only small number of patients who are highly prone to ischemic attacks. Before preclinical post-stroke experiments are conducted there are “proof of principle” questions that need to be addressed. Delivery to the intact brain via the ventricular system, vascular system or intranasal route needs further development. The increased permeability of blood brain barrier (BBB) after the onset of stroke, provides a window to target ischemic brain tissue for compounds that normally do not cross BBB. Other problems that need to be studied include the ability of post-stroke MANF delivery to promote recovery, timing of administration after stroke, and efficacy of coadministration of MANF with other treatments, like physical therapy or exercise, to promote recovery. Also, pre-clinical studies of MANF in other animal models of ischemic brain injury are needed. After these issues are addressed, safety, tolerance and efficacy of delivery should be evaluated in humans. Ultimately, a clinical study in a small number of stroke patients could be considered."
"The possible systemic administration of AAV, may lead to over-expression of MANF in other than the target brain area, which may have side effects. The unwanted over-expression can be controlled using cell-specific or synthetically regulated (e.g. small molecule regulation) promoters. Together with ruptured BBB, AAV containing regulated promoters may enable a less invasive means to deliver and control transgene expression in the penumbra of the infarcted brain. Future studies are needed to confirm the feasibility of this approach."
I thought perhaps one of the major shareholders might want to take some profits before it gaps higher. :)
I've hit my 15 message limit for the day.
Have a great weekend!!!!
Enjoy the Super Bowl.
I appreciate the fact that some of the recent buyers have already lost almost 60% of their investment but at some point doesn't common sense enter the picture?
The company lost almost $3,000,000 in the first nine months of 2012 with three employees. That is a fact.
According to the most recent statement published by the MJFF Amarantus is not currently under consideration for additional grants. That is a fact.
The company most recent financing "apparently" allows for conversion at .10 although there may be other undisclosed conditions that change the conversion price substantially.
If $2,000,000 garners the lenders .10 shares why wouldn't $15,000,000 get the lenders .06 shares?
Read the 2009 study that compared MANF to GDNF. It showed that in a number of instances that GDNF surpassed MANF. I guess if you conduct enough studies one might eventually support your position.
I don't see any reason for this to go higher before the dilutive funding is announced.
I had a buy order in today at .015 for 5,000,000 shares but no one would sell them to me.
Do you think it was because it was AON?
Based on today's volume it appears that someone wanted shares.
It's time for my "broken record" prediction of news next week. :)
I noticed that there is was still strong support on level 2 for shares at .015. 6,000,000 shares on the bid?
GLTA
p.s. 49'ers winning the "Super Bowl" is quite appropriate with "BONZ" reporting production revenues soon.
"Enough talk about wells" "ROFLMAO"
I thought I posted that exact sentiment four months ago.
Actually I think it was more along the line of beating a dead horse.
"Fools rush in where wise men fear to tread."
The shorts/sellers are walking this down to perfection. 2-3% every day until the new dilutive funding takes it below .035.
Have a great weekend. I'm expecting it to open below .08 on Monday.
p.s. The traders aren't even here anymore as they know there is no upside.
There's a bid for 5,000,000 shares at .015 on Level 2 also.
True. However if the company is willing to give .10 shares to get $2,000,000 I have to believe they'll give .06-.07 shares to raise $15,000,000.
Market typically discounts 30-40% from the price of the offering.
.04 as a low sounds reasonable.
This is headed to .03. I told you to sell.
1,000,000,000 shares is a lot.
Most of the individuals that are "pumping" the stock on the board with old news are probably holding their shares at a loss. Most of the individuals that purchased shares below .07 sold them when the share price was in the .18-.19 range.
With substantial dilution on the way I can understand why they are doing their best to convince others to buy the stock in an attempt to spike it again. I just don't see any upside until the terms of the next secondary offering is announced.
The company had indicated at the One Med Forum (posted on the site) that it was seeking a $1,000,000 bridge loan as it attempted to secure $15,000,000 in additional funding.
I can't imagine investors investing $15,000,000 without getting a share price in the .05-.06 range.
All imho.
p.s. Typically the market discounts 30% from the offering price which would be in the .035 range.
The company lost almost $3,000,000 in the first nine months of 2012 with only three employees. Why would you think it could afford its own lab?
Years and millions of dollars in investment before either of them may be approved for commercial use.
That's why the company authorized 1,000,000,000 shares.
Save your money. I think it would be a waste of time.
It seems that the individuals that have visited the site all agree that mining is on-going but as far as I know none of them have returned from their visit indicating that they were so impressed that they're buying more shares.
What does that tell you?
I hope you were smart enough to take some profits when the share price was above .11.
There is no upside here until the details of the secondary offering is announced.